title: Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts".
authors.affiliation: Department of Cardiovascular and Respiratory Medicine, University of Birmingham, Birmingham, UK.
authors.forename: Stavros
authors.initials: S
authors.lastname: Apostolakis
authors.forename: Deirdre A
authors.initials: DA
authors.lastname: Lane
authors.forename: Amitava
authors.initials: A
authors.lastname: Banerjee
mesh_terms: D001281:Atrial Fibrillation / Q000188:drug therapy*; D004617:Embolism / Q000517:prevention & control*; D015951:Factor Xa / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D009025:Morpholines / Q000008:administration & dosage*; D020521:Stroke / Q000517:prevention & control*; D013876:Thiophenes / Q000008:administration & dosage*; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D009025:Morpholines; D013876:Thiophenes; D014812:Vitamin K; D015951:Factor Xa